2/4
06:44 am
hrow
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/3
05:00 am
hrow
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Medium
Report
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
2/2
07:00 am
hrow
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Medium
Report
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
1/22
06:23 pm
hrow
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
Medium
Report
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]
1/19
06:15 am
hrow
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
Low
Report
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]
12/3
10:37 am
hrow
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]
Medium
Report
How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]
12/1
08:02 am
hrow
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]
Medium
Report
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]
11/24
07:00 am
hrow
Harrow to Present at Two Investor Conferences in December
Neutral
Report
Harrow to Present at Two Investor Conferences in December
11/18
07:00 am
hrow
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Low
Report
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals